Recruiting
Phase 3

Ivonescimab

Sponsor:

Summit Therapeutics

Code:

NCT05899608

Conditions

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ivonescimab Injection

Pembrolizumab Injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Summit Therapeutics on 2025-03-21.